Skip to content
type1.science
Phase 2RecruitingNCT07224321

INHALE-1st: Afrezza for youth with newly diagnosed T1D

What this study tests

MannKind phase 2 single-arm study of Afrezza (Technosphere insulin) plus basal insulin in children and adolescents aged 6 to under 18 with newly diagnosed stage 3 type 1 diabetes.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-08-13.

Most recent recorded citation date: 2026-08-13. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Youth aged 6 to under 18 with newly diagnosed stage 3 type 1 diabetes who can start Afrezza plus basal insulin within 21 days of the first insulin dose. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted. Recruiting; estimated n=100; started 4 February 2026; estimated primary completion March 2027. Live registry ages are 6 to under 18 (was written as 10 to under 18). Last update 13 August 2026.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Percentage of participants with CGM-measured time-in-range at least 70% at 13 weeks

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]